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ABSTRACT
Chikungunya virus (CHIKV) is an alphavirus transmitted by mosquitoes that is known to cause severe arthritis andmyositis in
affected patients. The ongoing epidemic began in eastern Africa in 2004 and then spread to islands of the Indian Ocean, India,
and Southeast Asia, ultimately afflicting millions. During this outbreak, more severe disease manifestations, including fatalities,
have been documented. The reasons for this change in pathogenesis are multifactorial but likely include mutations that have
arisen in the viral genome which could alter disease pathogenesis. To test this hypothesis, we used a murine model of CHIKV to
compare the disease pathogeneses of two recombinant strains of CHIKV, the first derived from the La Reunion outbreak in 2006
(LR2006 OPY1) and the second isolated from Senegal in 1983 (37997). While the two strains exhibited similar growth in mam-
malian cells in vitro, we observed more severe clinical disease and pathology in mice infected with the LR2006 OPY1 strain of
CHIKV, which included prolonged viremia and elevated viral titers and persistence in the muscle, resulting in devastating myo-
necrosis. Both CHIKV strains infected connective tissue fibroblasts of the muscle, but only the LR2006 OPY1 strain replicated
within myofibers in vivo, despite similar growth of the two strains in these cell types in vitro. However, when the 37997 strain
was administered directly into muscle, myofiber infection was comparable to that in LR2006 OPY1-infected mice. These results
indicate that differences in the ability of the strain of CHIKV to establish infection in myofibers may contribute to the increased
disease severity.
IMPORTANCE
CHIKV is an emerging pathogen that causes significant morbidity. Little is known about the pathogenesis of the disease, and this
study suggests that the ability of a recent epidemic strain to infect myofibers results in increased disease severity. Better under-
standing of how CHIKV causes disease contributes to the ultimate goal of creating therapeutics to alleviate the impact of this
debilitating virus.
Chikungunya virus (CHIKV) is a mosquito-borne alphavirusin the Togaviridae family. It was first identified in 1952 in
Tanzania andwas named in theMakonde language for the painful
arthritis it causes (1). Since then, periodic outbreaks of chikungu-
nya fever have been reported intermittently in Africa and Asia.
CHIKVwas brought to attentionmost recently when an outbreak
began in 2004 in Kenya. In short order, the virus spread to sur-
rounding countries and islands off the coast. In 2006, nearly 40%
of the population of La Reunion island was infected, and between
3 to 6.5million cases are estimated to have occurred in India from
2006 to 2008 (2). Unlike previous outbreaks, which have been of
limited duration, this epidemic has continued into 2013, with
spread throughout India and into Malaysia and Thailand.
In previous outbreaks, CHIKV had behaved like the “Old
World” alphaviruses, such as Sindbis virus or Ross River virus
(RRV), with the disease characterized by abrupt high fever, inca-
pacitating polyarthritis, and skin manifestations (3, 4). While
quite debilitating, the infection is generally self-limited and is
cleared within 2 weeks by most patients. However, a subset of
patients can develop polyarthritis and tenosynovitis that can last
for months or even years following the initial infection (5–7).
Epidemiological studies from this ongoing outbreak have also re-
vealed more severe disease manifestations. Mortality due to
CHIKV infectionwas noted for the first time, with over 250 deaths
attributable to CHIKV infection occurring during the La Reunion
epidemic (8, 9). This increased mortality was observed predomi-
nantly in elderly patients with other comorbidities. Increased sus-
ceptibility of neonates to severe infection with subsequent long-
term sequelae has also been noted (8, 10). Furthermore, around
one-half of themotherswith ongoingCHIKV infection at the time
of delivery transmitted CHIKV to their offspring (11). Neonatal
infection consisted of fever, poor feeding, pain, and skin manifes-
tations, with severe illness presenting as encephalopathy, often
resulting in long-term sequelae (11).
The reasons for the increased severity during this outbreak are
likely multifactorial and include the larger scale of the outbreak,
more thorough documentation and follow-up by the medical
community, and novelmutations that have accrued in the current
circulating strain of CHIKV. The importance of these novel mu-
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tations has already been demonstrated by a recent study in which
an alanine-to-valine mutation at residue 226 in the E1 protein of
La Reunion strains of CHIKV was found to result in increased
infectivity of a new mosquito vector, Aedes albopictus, the Asian
tiger mosquito (12). The new vector is present in temperate re-
gions and may have contributed to autochthonous outbreaks in
France and Italy, and it has potential to spread the disease inNorth
America as well (13–15). It is therefore also possible that some of
the novel mutations could contribute to the increased disease pa-
thology observed during this ongoing outbreak.
To test for differences in disease pathogenesis, we used the
neonatal model of CHIKV infection. The infection of neonatal
mice recapitulatesmany of the clinical and histological findings of
human CHIKV infection. Infected neonatal mice exhibit signifi-
cant viral dissemination to multiple tissues, develop neurological
signs of disease, and succumb to infection (16), similar towhat has
been observed in patients, especially in highly susceptible neo-
nates (11). Biopsy samples from patients that have been stained
for CHIKV antigen localize the staining to the muscle connective
tissue fibroblasts and satellite cells (17). An evaluation of CHIKV
localization following the infection of 9-day-old mice also local-
ized CHIKV to the muscle fibroblasts, which support muscle
health, as well asmyoblasts (16). Finally, while the pathogenesis of
alphavirus-induced disease is incompletely understood, the in-
flammatory response clearly contributes to disease. The expres-
sion of proinflammatory cytokines, including interleukin-6 (IL-6)
and IL-1, correlates with the severity of CHIKV-induced disease
in patients (18). In the neonatal mouse model, we observe the
induction of these proinflammatory cytokines following infec-
tion. Therefore, the infection of neonatal mice recapitulates many
of the clinical and histological findings of human CHIKV infec-
tion and provides us with a small-animal model to evaluate po-
tential differences in disease pathogenesis between the CHIKV
recombinant clones.
To evaluate whether an epidemic strain of CHIKV differs in
disease characteristics fromapast strain fromaprevious outbreak,
we utilized a recombinant clone of CHIKV isolated from the La
Reunion outbreak in 2006 (LR2006 OPY1) and compared this to
an earlier recombinant clone isolated from Senegal in 1983
(37997). The 37997 strain belongs to the West African clade of
CHIKV, while LR2006 belongs to the East Central South African
clade, which diverged many years ago (19, 20); the LR2006 OPY1
strain has sequence changes similar to those of other clinical iso-
lates from the Indian Ocean outbreak (21). An earlier analysis of
these two recombinant clones found that the LR2006 OPY1 strain
showed increased infectivity of and transmission by A. albopictus,
though the two strains grow similarly in C6/36 cells derived from
A. albopictus (12, 22). We observed that despite similar in vitro
growth in various mammalian cell types, the LR2006 OPY1 strain
displayed a more severe disease phenotype, resulting in hind limb
weakness and high muscle titers in neonatal mice. While both
strains were able to infect muscle connective tissue fibroblasts
early in infection, only LR2006OPY1was able to infectmyofibers.
However, this was not due to a difference in tropism, as both
strains were able to replicate in myoblasts and myofibers in vitro.
When 37997was injected directly into themuscle,myofiber infec-
tion comparable to that of LR2006 OPY1 was observed. This sug-
gests that the ability of a viral strain to establish infection in myo-
fibers can impact the severity of infection.
MATERIALS AND METHODS
Mice. Mice were maintained at Washington University School of Medi-
cine in accordance with all federal and university guidelines. For mouse
studies, the principles of good laboratory animal care were adhered to in
strict accordance with the recommendations in theGuide for the Care and
Use of Laboratory Animals of the NIH (23). The protocols were approved
by the Animal Studies Committee at Washington University. All efforts
were made to minimize suffering. C57BL/6 and alpha/beta interferon
(IFN-/) receptor 1 (IFNAR/) mice on the C57BL/6 background
were bred and maintained in our mouse colony. For neonatal experi-
ments, mice were infected at 6 days of age. Litters were weight matched at
the initiation of the experiments.
Virus production. The construction of recombinant plasmids for the
LR2006 OPY1, 37997, LR2006-green fluorescent protein (GFP), and
37997-GFP strains of CHIVK has been previously described (19, 20). Re-
combinant viral stocks were generated from viral cDNA clones by in vitro
transcription of linearized cDNA templates followed by RNA transfection
with Lipofectamine 2000 (Invitrogen) into baby hamster kidney 21 cells
(BHK cells) as previously described (24). After 48 h, the supernatant was
collected, centrifuged, aliquoted, and stored at 80°C. Titers of viral
stocks were determined by plaque assay as previously described (25). All
work with live virus was performed in a biosafety level 3 facility and fol-
lowed strict guidelines established by the Environmental Health and
Safety committee at Washington University School of Medicine.
Cells. Murine embryonic fibroblasts (MEFs) were generated from
C57BL/6 or IFNAR/mice and were grown in Dulbeccomodified Eagle
medium (DMEM) (Mediatech) supplemented with 10% fetal bovine se-
rum (FBS) (Sigma), 1% penicillin-streptomycin (Mediatech), 1% L-glu-
tamine (Mediatech), and 1%HEPES (Mediatech). MEFs were used prior
to passage number 5 for these studies. Primary muscle fibroblasts were
isolated from newborn mice as previously described (26). Briefly, skeletal
muscle obtained from newborn mice was dissected and digested with
collagenase (Worthington). Cells were cultured in F12 medium (Invitro-
gen) with 10% FBS and 1% penicillin-streptomycin for 2 days before
replating the cells for growth curve analysis. C2C12 cells were obtained
from ATCC (ATCC CRL1772) and cultured as recommended. To obtain
myofibers, C2C12 cells were plated at 5 104 cells/well in 24-well plates,
differentiated into myofibers by the substitution of 2% horse serum for
FBS, and then cultured for 10 days prior to infection as described below.
Viral growth curves.MEFs, primary connective tissue fibroblasts, and
C2C12 cells were grown and/or differentiated as described above. For viral
growth curves, MEFs were plated at 1  105 cells/well and all other cell
types were plated at 5  104 cells/well in 24-well tissue culture-treated
plates and allowed 24 h to adhere. For interferon sensitivity assays, cells
were then either pretreated with IFN- (PBL InterferonSource) at the
indicated dose or mock treated with medium only for 24 h. Cells were
infected at the indicatedmultiplicity of infection (MOI). Cells were rinsed
with DMEM with 1% FBS, after which diluted virus was added and al-
lowed to adhere for 1 h. The virus was then aspirated and replaced with
fresh medium. At each time point, a plate was frozen at 80°C and un-
derwent three freeze-thaw cycles before titers were determined on BHK
cells by standard plaque assay.
Viral studies. Six- to nine-day-old pups were infected with between
5  104 and 1  105 PFU of the indicated recombinant CHIKV clone
(37997 or LR2006 OPY1) diluted in 15 l of phosphate-buffered saline
(PBS) and injected intradermally (i.d.) to mimic a mosquito bite, using a
Hamilton syringe and 30-gauge needle, into the left upper pectoral area.
For survival experiments, pups were monitored daily for clinical signs of
disease (including ruffling of fur, altered gait, and hind limbparalysis) and
lethality for 21 days postinfection (dpi). For viral titers, the mice were
infected as described above and the various tissues (injection site, serum,
muscle, and brain) were harvested into PBS and stored at 80°C. Injec-
tion site refers to the skin and underlying connective tissue and fat at the
site of infection. Serum samples were pooled when collected, with each
sample containing sera from two mice from a single experiment. For
CHIKV Myoﬁber Infection in Mice
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muscle titers, the hind limb ipsilateral to the site of infection was skinned
and the hamstring was collected. For the analysis of viral loads, the sam-
ples were homogenized with 100 l of 1.0-mm-diameter zirconia-silica
beads using aMagnaLyzer (Roche) by alternating two pulses of 7,000 rpm
for 30 s each, with chilling on ice for 30 s. The homogenates were serially
diluted, and titers were determined by plaque assay on BHK cells. For
serum collection, pups were bled at the designated time postinfection into
BD Serum Separator tubes. These were spun for 9 min at 12,000 g and
then frozen at80°C until their titers were determined.
Histopathology. Six-day-old pupswere infected i.d. with 5 104 PFU
of either CHIKV recombinant clone or were mock infected i.d. with PBS
in the left upper pectoral area. Mice were sacrificed at the indicated day
postinfection, and the hind limb and brain were fixed with 10% formalin
for 48 h at room temperature and then rinsed with PBS for 15 min and
stored in 70% ethanol at 4°C until being submitted for embedding in
paraffin blocks and sectioning. The sections were stained with hematox-
ylin and eosin to examine for histopathology. Embedding, sectioning, and
staining were performed by the Anatomic and Molecular Pathology His-
tology Core at Washington University in St. Louis. All slides were evalu-
ated and scored blindly by one of the authors (J.C.C.) for the presence of
histopathological changes consistent with mengoencephalitis in the brain
samples and for histological changes within the muscle. Changes in the
muscle were scored as follows: 0, normal; 1, predominantly normal tissue,
only minimal chronic inflammatory infiltrates and some regenerative
fibers; 2, focal, mild chronic inflammatory infiltrates and some degener-
ation/regeneration; 3, mildmyonecrosis with chronic inflammatory infil-
trates and degeneration/regeneration; 4, moderate myonecrosis with
chronic inflammatory infiltrates and degeneration/regeneration; and 5,
severe myonecrosis with chronic inflammatory infiltrates and degenera-
tion/regeneration.
Cytokine/chemokine analysis. Sera were harvested from infected
mice at the indicated time points and stored at80°C for analysis. Serum
cytokine levels were measured using Luminex technology with the Bio-
plex Pro mouse cytokine 23-plex assay (Bio-Rad).
Immunofluorescence. For immunofluorescence experiments, the
micewere infected as described above, but we utilized recombinant clones
for the 37997 and LR2006 OPY1 strains expressing green fluorescent pro-
tein (GFP) (19). For intradermal infections, 1  105 PFU of either GFP
strain was injected into the skin of the upper left chest of 6-day-old pups.
For intramuscular (i.m.) injections, 2.5  104 PFU of either the GFP-
expressing, or parental recombinant strains was injected directly into the
left hamstrings of 6-day-old pups. Tissue was harvested from the mice at
the indicated times and fixed in 4% paraformaldehyde for 24 h at 4°C. It
was then rinsed with PBS for 24 h and allowed to equilibrate in 30%
sucrose for 2 h before embedding in OCT. Sections were cut using a
cryostat and blocked with 5% normal goat serum (Sigma). Sections were
stained with an anti-collagen IV antibody (Abcam) andwith DAPI (4=,6=-
diamidino-2-phenylindole) (Vector Laboratories). The slides were devel-
oped with a donkey anti-rabbit 546 secondary antibody using Alexa Fluor
(Invitrogen).
Quantification of histology. Photographs were taken using a Nikon
Eclipse 80i microscope and processed with Metamorph software (Molec-
ular Devices). To quantify, 6 high-power (40 or20) fields (hpf) were
taken per section, with a single section per mouse. For i.m. injections,
GFP-positive (GFP) and GFP-negative fibers were counted in each hpf,
and the percent positive cells was calculated. For i.d. injections, only
GFP cells per hpf were counted. The mean and standard error of the
mean (SEM) of all high-power fields per sections were used to calculate
significance.
RT-PCR. Mice were infected with 1  105 PFU i.d. Tissues were ex-
cised and flash frozen in liquid nitrogen. Tissues were homogenized using
the MagnaLyzer (Roche), and RNA was extracted using the RNeasy
fibrous tissue kit (Qiagen). RNAwas used to run real-timePCR (RT-PCR)
on the infected tissues, normalizing to GAPDH (glyceraldehyde-3-phos-
phate dehydrogenase) (IDT). Monocyte chemoattractant protein 1
(MCP-1), RANTES, and interferon-stimulated gene 15 (ISG15) gene ex-
pression assays were purchased from Applied Biosystems. IFN- primers
and probes were provided courtesy of Michael Diamond (Washington
University, St. Louis, MO) and are forward primer 5=-GGC TTC CAT
CAT GAA CAA CAG-3=, reverse primer 5=-GTT GAT GGA GAG GGC
TGT G-3=, and probe 5=-5/6FAM/CTG CGT TCC TGC TGT GCT TCT
C/36-TAMSp/-3=. Pan-IFN- primers and probeswere used as previously
reported (27).
ELISA. Mice were infected with 1  105 PFU i.d., and serum was
harvested at the indicated time points and stored at 80°C. An IFN-
enzyme-linked immunosorbent assay (ELISA) kit from PBL Interferon-
Source was used according to the manufacturer’s instructions.
Chimeric viruses. Chimeric viruses were constructed using a method
described previously (28). Briefly, the E2 region of each strain was ampli-
fied using the forward primer 5=-AATGTCTATAAAGCCACAAGAC-3=
and the reverse primer 5=-ACGTTGACAGACTCTGAGAA-3=. The seg-
ments were gel extracted and used as primers for the next PCR with the
opposite strain with the QuikChange II XLmutagenesis kit (Agilent). The
reaction mix then underwent an initial incubation for 1 min at 98°C,
followed by 18 cycles of 98°C for 30s, 60°C for 30s, and 72°C for 8min and
a final extension of 72°C for 10 min. Clones were sequenced using the
forward and reverse primers. Viruses were then generated as described in
“Virus production” above.
Statistical analysis. All data were analyzed using the Prism software
(GraphPad Software, San Diego, CA). Survival data were analyzed using
Gehan-Breslow-Wilcoxon test, with death as the primary variable. Acute-
titer data and cytokine data were analyzed using the Mann-Whitney test.
Errors bars in figures represent the standard error of the mean.
RESULTS
CHIKV strains 37997 and LR2006OPY1 display similar growth
and sensitivity to an IFN--induced antiviral state in primary
MEFs. A previous comparison of the sequences of the 37997 and
the LR2006 OPY1 strains of CHIKV revealed 162 amino acid dif-
ferences between these two strains (22). Since these differences
could impact the ability of these viruses to replicate, we first
wanted to evaluate their growth in mammalian cells prior to eval-
uating potential differences in pathogenesis. Both BHK cells and
MEFs were infected with the two strains of CHIKV at a lowMOI,
and viral growth over time was analyzed. Both the LR2006 OPY1
and the 37997 strains of virus grew with similar kinetics in BHK
cells (data not shown).We also observed no difference in the viral
growth rate or in the peak viral titers achieved in MEFs infected
with either strain at any of the time points analyzed (Fig. 1A).
Previous studies with other alphaviruses have shown that mu-
tations controlling the sensitivity of a virus to type I interferons
could impact its in vivo pathogenesis (29, 30). Mutations mapped
to the 5= nontranslated region and the nsP1 and nsP2 genes in
Sindbis virus have been found to affect interferon sensitivity (29,
30). There are residue differences in these genes between the
LR2006 OPY1 and 37997 strains (22). Therefore, we next tested
whether the two strains of CHIKV displayed similar in vitro sen-
sitivities to type I IFNs. C57BL/6 MEFs were either mock treated
or treated for 24 h prior to infection with IFN- at a dose that
would induce an antiviral response and partially inhibit viral rep-
lication. The cells were then infected, and viral growth was mon-
itored at several time points postinfection. As seen in Fig. 1B
(dashed lines), IFN pretreatment was able to equivalently inhibit
both the LR2006 OPY1 and the 37997 strains of CHIKV. We also
observed a similar increase in replication of the two CHIKV
strains following the infection of IFNAR/MEFs, with the virus
growing to titers that were nearly 100-fold higher than in B6MEFs
Rohatgi et al.
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(Fig. 1C). As expected, pretreatment of these cells had no impact
on CHIKV replication. Together, these results indicate that the
LR2006 OPY1 and the 37997 recombinant clones of CHIKV dis-
played similar growth kinetics in mammalian cells and similar
sensitivities to IFN in vitro.
The LR2006OPY1 strain of CHIKV inducesmore severe dis-
ease than the 37997 strain of CHIKV. Next, we evaluated the
pathogeneses of these two clones using a neonatal murine model
of CHIKV infection. In this model, the infection of wild-type
(WT)mice less than 10 days of age results in the development of a
disseminated infection with significant lethality (16, 31). We in-
fected 6-day-oldC57BL/6 pups i.d. in the upper left chest with 5
104 PFUof either the LR2006OPY1 or the 37997 strain of CHIKV.
Infection with either strain of CHIKV resulted in significant
lethalitywith a similarmedian onset of lethality of 10 days for both
viruses, with 54% of the LR2006 OPY1-infected pups and 68% of
the 37997-infected pups succumbing to infection (Fig. 2A). How-
ever, despite the similarity in lethality induced by both strains of
CHIKV, we observed more severe clinical signs of disease in the
LR2006 OPY1-infected pups than in the 37997-infected mice.
Whilemice infected with either strain of CHIKV displayed ruffled
fur, sluggishness, and altered gait, the LR2006 OPY1-infected
mice often developed hind limb weakness and paralysis, which
were rarely seen in the 37997-infectedmice (data not shown). This
severe weakness was first observed at 7 days postinfection (dpi)
and lasted throughout the course of infection in surviving mice.
To further investigate the differences in the clinical courses
induced by the two strains, we next evaluated viral dissemination
and replication of the two clones in six-day-old mice at different
times postinfection. An analysis of the injection site, which in-
cluded the skin and underlying connective tissue, revealed similar
viral loads at all of the time points analyzed, with peak titers ob-
tained at 1 dpi and a steady decrease in viral replication until 9 dpi,
when replicating virus was no longer detected (Fig. 2B). It has
been previously reported that in the neonatal model of CHIKV
infection, mice develop viremia, resulting in viral dissemination
to multiple tissues. Mice infected with either strain of CHIKV
developed viremia, with similar viral levels detected in the LR2006
OPY1- and the 37997-infected mice at both 1 and 3 dpi (Fig. 2C).
However, mice infected with the 37997 strain cleared the virus
from the serum by 4 dpi. In contrast, mice infected with the
LR2006 OPY1 strain maintained persistent viremia until 7 dpi,
when serum viremia was no longer detected.
The hind limbweakness and ataxic gait that we observed in the
LR2006 OPY1-infected mice could be due to CHIKV infection
impacting either the central nervous systems or the muscles, or
both, of thesemice. Therefore, we evaluated viral loads in both the
brains and the muscles of mice infected with either the LR2006
OPY1 or the 37997 strain. While we did observe an increase in
viral titers in the brains of the LR2006 OPY1-infected mice at 3
and 4 dpi, by 5 dpi similar titers were observed in mice infected
with either CHIKV strain, and both strains were cleared by 12 dpi
in surviving mice (Fig. 2D). Furthermore, histological evaluation
of the brains from these mice at the various times postinfection
revealed no significant pathology induced by either strain of
CHIKV (data not shown). In contrast to the case for the brain, an
analysis of viral titers in the muscle revealed a striking difference
between the two strains.We found that infectionwith either strain
of CHIKV resulted in detectable viral titers in the muscle as early
as 1 dpi (Fig. 2E). Consistent with our clinical observations, how-
ever, the LR2006 OPY1-infected mice had significantly greater
viral burdens in their muscles. By 3 dpi the mice infected with the
LR2006 OPY1 strain of CHIKV displayed greater than 100-fold
more virus in their muscles than those infected with the 37997
strain, even though serum viral loads were similar for the two
strains at this time point. The increased viral burden observed in
the muscles of the LR2006-infected mice persisted until at least 9
dpi, with the LR2006 OPY1-infected mice having between 3- and
4-log-higher viral titers in their muscle (Fig. 2E). Mice infected
with the 37997 strain had peak replication at 5 dpi with a mean
titer of 3.0 104 PFU/ml, while the LR2006OPY1 strain peaked at
6 dpi with a mean titer of 6.17 107 PFU/ml (Fig. 2E). While the
37997 strain was largely cleared from the muscle by 9 dpi, mice
infected with the LR2006 OPY1 strain continued to have greater
than 10,000-fold more virus, even at 9 dpi. Even increasing the
infecting dose of 37997 to 20 times the dose (2 106 PFU i.d.) did
not result in an increase in viral loads detected in the muscles of
the infected mice (data not shown). To determine if the adaptive
immune response played a role in clearing the viral infection from
the muscle, we also infected Rag/ mice with either strain of
CHIKV and observed no differences in viral loads compared to
those in WT mice (data not shown). Therefore, consistent with
the hind limb weakness observed in the mice infected with the
LR2006 OPY1 strain of CHIKV, we observed increased peak viral
loads and prolonged replication in the muscles of mice infected
with the LR2006 OPY1 strain.
LR2006 and 37997 elicit similar serum type I IFN and proin-
flammatory cytokine and chemokine responses during the
FIG 1 Recombinant CHIKV strains LR2006 OPY1 and 37997 display similar growth characteristics in vitro. (A) WTMEFs were infected at an MOI of 0.05 for
1 h and analyzed for titer by plaque assay at several time points postinfection. (B and C) WTMEFs (B) or IFNAR/MEFs (C) were pretreated with 8 U/ml of
IFN- for 24 h before infection and then infected at an MOI of 0.05 for 1 h, and titers were determined by plaque assay as for panel A. Growth curves were
determined in two independent experiments, each in duplicate.
CHIKV Myoﬁber Infection in Mice
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course of infection. One explanation for the dramatic difference
in viral titers could be altered production of type I IFNs by the two
viruses or perhaps differential antagonism of this response. To
begin to assess this possibility we first evaluated whether there was
a difference in the systemic induction of type I IFNs by the LR2006
OPY1 and the 37997 strains of CHIV. Mice were infected with
either the LR2006OPY1 or the 37997 strain of CHIKV, and serum
IFN- levels were measured at various time postinfection (Fig.
3A).We detected very little IFN at 8 h postinfection. Levels peaked
at 16 h postinfection and slowly diminished during the next 48 h.
However, we observed no differences in the levels of systemic
IFN- induced by either viral strain. Since we observed the largest
differences in viral loads in the muscles of infected mice, we also
evaluated the type I IFN response in the muscles of mice infected
with either strain of CHIKV. RT-PCR was used to measure the
levels of IFN-, IFN-, or ISG15 in the hind limb muscle at vari-
ous times postinfection (Fig. 3B).While the expression of all three
was increased compared to levels in mock-infected mice, there
was no difference in the induction of IFN-, IFN-, or ISG15
between the different CHIVK strains. Based upon this analysis, it
does not appear that the differences in disease pathogenesis seen in
the LR2006 OPY1 and the 37997 strains of CHIKV are due to
differences in the induction of type I interferon.
We have previously seen that neonatal mice infected with
CHIKV develop a systemic inflammatory response (25). Further-
more, in a neonatal model of Sindbis virus infection, this systemic
inflammatory cytokine response likely contributes to the lethality
(32).We therefore next determined if there was a difference in the
cytokines induced by either the 37997 or LR2006 OPY1 strain of
CHIKV that may account for the differences in pathogenesis that
we observed. We analyzed 23 cytokines and chemokines in the
sera of infected mice at 1, 3, 5, and 7 dpi. As previously observed,
several cytokines were induced by CHIKV infection, including
IL-1, IL-1, IL-6, IL-10, and granulocyte colony-stimulating
factor (G-CSF) (Fig. 3C). Both CHIKV strains induced elevated
levels of IL-1, IL-6, and RANTES, cytokines found to be associ-
FIG 2 LR2006 OPY1 achieves higher muscle titers and persistence in the serum. Pups were infected i.d. at 6 days of age with 5 104 PFU of either the LR2006
OPY1 or 37997CHIKV strain. (A) Infectedmiceweremonitored for clinical signs of disease and death each day until 21 days postinfection. (B to E) Infectedmice
were harvested at the indicated time points; injection site (B), serum (C), brain (D), and distal hind limb muscle (E) were collected, and titers were determined
by plaque assay (n 5 to 8 pups per group per time point, except at 12 dpi, where n 4 pups per time point). The dashed lines indicate the limit of detection
for the assay. Significance for survival was evaluated by both the log rank and the Gehan-Breslow-Wilcoxon tests. Statistical significance for panels B to E was
evaluated with the Mann-Whitney test. *, P 0.01 to 0.05; **, P 0.001 to 0.01; ***, P	 0.001; N.S., not significant.
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ated with severe disease in human patients afflicted with CHIKV
(18). Surprisingly, despite the increased viral loads detected in the
LR2006 OPY1-infected mice during the course of viral infection,
we observed no significant difference in the cytokine levels between
the strains at any time point we analyzed. We did observe a trend
toward an increase in several chemokines, including KC, MCP-1,
MIP-1, MIP-1, and RANTES, at 1 dpi in mice infected with the
37997 strain of CHIKV (Fig. 3C), although these differences did not
reach statistical significance. To determine whether elevations in
these chemokineswere alsopresent in themuscle,whereweobserved
the differences in viral titers, we analyzed the hind limb muscle for
expression of MCP-1 and RANTES RNAs by RT-PCR (Fig. 3D).
RNA levels of both chemokines were elevated over levels in mock-
infected mice as early as 1 dpi. However, we observed no differences
in the induction of eitherMCP-1 or RANTES RNA between the two
strains of CHIKV. At 7 dpi, the RNA levels of both chemokines were
further elevated, withmice infected with LR2006 expressing levels of
MCP-1 andRANTESRNAs similar to those inmice infectedwith the
37997 strain, despite the increased viral burden present in thesemice
at this time (Fig. 3D). Together, these results indicate that both the
37997 and the LR2006 OPY1 strains of CHIKV induce a systemic
cytokine and chemokine response in this neonatal model; however,
no significant differences in the responses induced by the two viral
strains were noted.
FIG 3 Similar type I interferon and proinflammatory cytokine and chemokine profiles are induced by both strains of CHIKV. Six-day-old pups were infected
with 5 104 PFUof either CHIKV strain ormock treatedwith PBS i.d. (A) Serawere collected from infectedmice at several hours postinfection, and IFN- levels
were measured by ELISA. The IFN- level in mock-infected mice was 8.37 pg/ml. (B and D)Mice were infected with 1 105 PFU of either CHIKV strain. RNA
was extracted fromhind limbmuscle, and RT-PCRwas performed. Samples were normalized toGAPDH. The dashed lines indicate RNA levels inmock-infected
mice. (C) Sera were collected at the indicated times and analyzed using a Bioplex Pro mouse 23-plex array. The dashed lines indicate the level of cytokine or
chemokine in mock-infected samples. n 4 per time point. The results did not reach statistical significance at any time points analyzed.
CHIKV Myoﬁber Infection in Mice




arch 1, 2014 by W






The LR2006 OPY1 strain of CHIKV infects myofibers and
results in greater hind limb muscle damage than the 37997
strain of CHIKV. To further characterize the disease induced by
these two CHIKV strains, we next performed a histological anal-
ysis of the muscles of infected mice. Muscle from the hind limb
distal to the site of infection was collected at various times postin-
fection and stained with hematoxylin and eosin (H&E). These
slides were evaluated by a pathologist in a blinded fashion.Muscle
sections were given a severity score from 0 (normal) to 5 (most
severe) as described in Materials and Methods. An analysis of the
muscles from CHIKV-infected mice revealed significant patho-
logical changes (Fig. 4A and B). In mice infected with the 37997
strain, we observed focal areas of myositis and necrosis, with the
majority of the muscle being largely undamaged. The peak dam-
age seen was at 9 dpi for 37997-infectedmice (Fig. 4B). Consistent
with the profound muscle weakness observed clinically and the
increased viral titers, muscle from mice infected with the LR2006
OPY1 strain displayed widespread destruction beginning at 5 dpi
and lasting until at least 12 dpi, with peak damage occurring at 12
dpi (Fig. 4A and B). In these samples there were dense inflamma-
tory infiltrates accompanying massive myonecrosis (mean
score  5 at 12 dpi) (Fig. 4A). Therefore, these histological data
support the clinical findings that the LR2006 strain of CHIKV
induces more severe muscle disease in these mice.
To further evaluate the differences seen in the muscles of these
mice, we next determined if there were differences in viral tropism
between the two strains. Previous work has shown that CHIKV
replicates in the connective tissue fibroblasts and myoblasts in
bothmice and humans (16).While other studies have notedmyo-
fiber necrosis and attributed this to infection of those fibers by
CHIKV, previous studies have not detected infection of the myo-
fibers (33).We utilized recombinant CHIKV strains inwhichGFP
expression was driven by a subgenomic promoter in either the
37997 or LR2006OPY1backbone.When these viruses are utilized,
only cells that harbor active CHIKV infection will express GFP.
Mice were infected i.d. with either the 37997-GFP- or LR2006-
GFP-expressing CHIKV strain, and at different times postinfec-
tion the hind limbmuscle was evaluated by immunofluorescence.
FIG 4 The LR2006 OPY1 strain induces dramatic myositis and necrosis. Six-day-old pups were infected with 5 104 PFU of CHIKV i.d. or were mock treated
with PBS. The hind limbwas isolated on the indicated days postinfection and fixed in 10% formalin for 48 h. Sections were submitted for embedding, sectioning,
and staining. (A)The pathology of each samplewas scored by a pathologist on a scale of 0 to 5 as described inMaterials andMethods. RepresentativeH&E-stained
sections at several days postinfection at a magnification of40 are shown, with the pathological score indicated in parentheses. (B) Graphical representation of
the scores of all of the histological sections. *, P 0.01 to 0.05.
Rohatgi et al.
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Similar to what has been previously reported, we detected GFP
staining in the connective tissue fibroblasts surrounding the mus-
cle fibers following infection with either the LR2006 or 37997
strain of CHIKV (Fig. 5A, top panels). Staining was detected as
early as 3 days postinfection and increased throughout the course
of infection until myofibers were destroyed. Quantification of
GFP fibroblasts revealed that similar quantities of cells were in-
fected following infection with either strain of CHIKV (Fig. 5B).
Surprisingly, inmice infectedwith LR2006OPY1,we also detected
GFP staining of the myofibers, particularly at late time points
after infection, although GFP fibers could be seen as early as 3
dpi. In contrast, there was almost a complete absence of GFP
myofibers in the hind limbs ofmice infectedwith 37997-GFP (Fig.
5A, bottom panels, and 5C). These data suggest that the ability of
the LR2006OPY1 strain to gain access to themyofibers and estab-
lish infection results in increased viral loads in the muscle and
increased muscle damage and likely contributes to the increased
pathogenicity of this CHIKV strain.
During i.m. injection, both strains are able to infect myofi-
bers. The inability of the 37997 strain to infect the myofibers fol-
lowing an intradermal infection could be due to an inability of the
virus to directly infect the myoblasts/myofibers, an inability to
grow in the myoblasts, or difficulty in gaining access to this com-
partment. To test these possibilities, we first evaluated the abilities
of the LR2006 OPY1 and 37997 strains to infect and replicate in
primary connective tissue fibroblasts and in myoblasts and myo-
fibers. Primary muscle connective tissue fibroblasts were isolated
fromneonatalmice and infectedwith either strain of CHIKV at an
MOI of 0.05. Viral growth was assessed at various times postinfec-
tion. The two strains grew at similar rates and reached comparable
peak titers after 48 h postinfection (Fig. 6A). This supported our in
vivo observation that both strains infected and replicated within
the connective tissue fibroblast compartment (Fig. 5A and B).We
next evaluated the abilities of the LR2006 OPY1 and 37997 strains
to infect and replicate within myoblasts and myofibers. We first
used the C2C12 myoblast cell line to assess growth in vitro. Both
CHIKV strains were able to infect the C2C12 cells, and an analysis
of viral growth revealed that the two strains displayed similar
growth kinetics (Fig. 6B). Next,myoblasts were differentiated into
myofibers, forming a mixed culture of both myoblasts and myo-
fibers. They were also infected with a low MOI, which produced
comparable growth of the strains (Fig. 6C). These results suggest
that both viral strains have the ability to infect connective tissue
fibroblasts, myoblasts, and myofibers. Furthermore, it appears
that the strains display similar growth characteristics in vitro.
Therefore, it does not appear that the 37997 strain cannot infect
and/or replicate in the myoblasts but rather appears that this viral
strain may not be able to gain access to this compartment in vivo.
To determine whether the difference in viral replication was
due to the inability of 37997 to infect myofibers in vivo, intramus-
cular injections were performed by injecting 2.5  104 PFU di-
rectly into the left hamstrings of six-day-old mice. Hind limb
muscle from the site of injection was collected and stained by
immunofluorescence. In contrast to the intradermal infection,
following the direct intramuscular administration of virus, both
37997-GFP and LR2006-GFP were able to infect myofibers, as
shown at 3 dpi (Fig. 6D), and the numbers of GFP myofibers
were similar for the two viral strains (Fig. 6E). At later time points,
massive tissue destruction was seen in mice infected by either
strain, and few GFPmyofibers remained (data not shown). This
finding was further supported by an analysis of viral loads in the
muscle. Mice were infected with the parental strains of LR2006
OPY1 and 37997, which lack GFP, and viral titers in the infected
muscle were analyzed at different times postinfection. Following
direct inoculation, the two strains reached similar viral titers, with
only a 3.54-fold increase in titers in the LR2006 OPY1- versus the
37997-infected muscle, compared to the 1,000-fold difference
seen during i.d. administration (Fig. 6F). Following direct inocu-
lation, the 37997 strain reached peak titers of 6.77 105 PFU/ml,
much higher than its peak viral load following administration by
the i.d. route, despite using a lower inoculating dose of 2.5 104
PFU (Fig. 6F). The ability of the 37997 strain to replicate to high
FIG 5 Intradermal infection results in infection of myofibers by LR2006 OPY1 but not by 37997. Mice were infected with either 37997-GFP or LR2006
OPY1-GFP i.d. at a dose of 5 104 PFU. Muscle from the hind limb was stained for collagen IV (red), GFP (green), or nuclei (blue). (A) Top panels, muscle
harvested at 3 dpi (magnification,40); bottom panels, muscle harvested at 7 dpi (magnification,20). (B) Connective tissue fibroblasts were counted in40
high-power fields at 3 dpi. (C) Myofibers per20 high-power field at 7 dpi. Scale bars, 100 m.
CHIKV Myoﬁber Infection in Mice
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viral titers following direct i.m. inoculation indicates that the two
viral strains display similar fitness once they gain access to the
muscle fiber compartment. During the course of these direct in-
tramuscular infections, we once again noted that the contralateral
legs of the mice infected with the LR2006 OPY1 strain of CHIKV
developed severe weakness, while in the mice infected with the
37997 strain of CHIKV, we did not detect contralateral leg weak-
ness. When titers in the contralateral legs were determined, we
found that similar to the case for the i.d. route of infection, the
LR2006 OPY1-infected mice achieved significantly higher viral
titers in their contralateral legs than the titers obtained in the
37997-infected mice, with viral titers reaching 5.5 106 PFU/ml
in the LR2006 OPY1-infected mice at 5 dpi, compared to titers of
only 1.5 104 PFU/ml in the 37997-infectedmice (Fig. 6G). Thus,
injecting virus at a different location, in this case directly into the
muscle, does not alter its ability to spread throughout the host.
Taken together, these results demonstrate that both the LR2006
OPY1 and the 37997 strains of CHIKV have the ability to replicate
within the primary cells of the muscle, namely, the connective
tissue fibroblasts and the myoblasts when access is provided. The
differences in pathogenesis that we have seen in ourmodel appear
to reflect the ability of the LR2006 OPY1 strain to access the myo-
blast/myofiber niche, which it can do following either i.d. or i.m.
inoculation. In contrast, the 37997 strain of CHIKV, while able to
establish viremia and infect the connective tissue fibroblasts, fails
to establish a robust infection of themyoblasts/myofibers unless it
is provided direct access via i.m. inoculation. This results in de-
creased viral loads and diminished muscle damage.
DISCUSSION
The ongoing epidemic of CHIKV infection has highlighted the
need for a better understanding of the pathogenesis of this re-
emerging pathogen. The dominant disease presentation seen dur-
ing this outbreak consists of fever, rash, and arthritis, as in past
outbreaks. However, new reports suggest increased disease sever-
ity, including neurological symptoms and mortality that had not
previously been seen in CHIKV outbreaks. The reasons for altered
pathogenesis are multifactorial and include the large scale of the
outbreak, better reporting of CHIKV cases, and accrual of viral
mutations.
FIG 6 Both strains can infect muscle when given intramuscularly. (A to C) Primary muscle fibroblasts (A), C2C12 myoblasts (B), and differentiated C2C12
myofibers (C) were infected with either LR2006 OPY1 or 37997 at anMOI of 0.05, and titers were determined at various times postinfection by plaque assay. (D
and E) Mice were infected in the hind limb with 2.5 104 PFU LR2006 OPY1-GFP or 37997-GFP and sacrificed at 3 days postinfection. (D) Frozen sections of
hind limb muscle was stained for collagen IV (red), GFP (green), and nuclei (blue). Scale bar, 100 m. (E) Quantification of GFPmyofibers per high-power
field. (F and G)Mice were infected in the hind limb with the parental strains at 5 104 PFU; muscles ipsilateral (F) and contralateral (G) to the site of infection
were harvested at the indicated days, and titers were determined by plaque assay. *, P 0.01 to 0.05; ** P 0.001 to 0.01; *** P	 0.001.
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In this study, we compared the pathogeneses of two different
CHIKV strains, one isolated during the La Reunion outbreak in
2006 and another isolated from Senegal in 1983. Importantly,
both viruses utilized in these studies were generated from recom-
binant clones to minimize viral heterogeneity. The clones were
not mouse adapted and represent viruses that were actively circu-
lating when isolated. Neonatal mice infected with the La Reunion
recombinant strain (LR2006 OPY1) developed more severe dis-
ease, with progressive hind limb weakness and severe myonecro-
sis, than those infected with the Senegal strain (37997). 37997 and
another strain from the 2006 outbreak (DHS-4263) were also
compared in a macaque model, where slightly elevated viremia
was seenwith the 37997 strain (33).Mildmuscle fiber necrosis was
also seen in several animals, but muscle titers or pathology during
acute infection was not determined (33). In the murine arthritis
model, more severe joint swelling was seen in mice infected with
the LR2006 OPY1 strain than in those infected with an Asian iso-
late from the 1960s (34). Additional studies that carefully evaluate
viral pathogenesis and correlate this with myofiber infection will
be important to perform to try to identify the viral determinants
contributing to this phenotype.
The most striking difference in the disease induced by each
strain was the very high muscle titer in the mice infected with
LR2006 OPY1, which resulted in severe myonecrosis (Fig. 2E and
4). Both strains are able to spread from the site of infection and
establish infection in the distal muscle by infecting connective
tissue fibroblasts early in infection. CHIKV has been shown to
infect this cell type in murine models and in human biopsy spec-
imens (16). However, as early as 3 dpi, when viral loads in the
serum were similar for the two strains, mice infected with the
LR2006 OPY1 strain had viral titers within their hind limb mus-
cles that were 1,000-fold greater than those observed in the 37997-
infected mice. This increased viral load persisted until at least 9
dpi. Most strikingly, this increase in viral replication correlated
with the ability of the LR2006 OPY1 strain, but not the 37997
strain, to infect the myofibers within the muscle.
There are several hypotheses that could explain the difference
in behavior between the 37997 and LR2006 OPY1 strains. These
include differences in viral fitness, viral tropism, and access to
myofibers. A recent study of Ross River virus identified a single
amino acid change within the E2 protein (Y18H) that resulted in a
dramatic reduction in muscle titers and pathology. This switch to
histidine resulted in a decrease in the fitness of this virus in mam-
malian cells, resulting in reduced replication in both murine and
human cells but an increased ability to replicate in mosquito cells
(35). An alignment of the E2 proteins from the LR2006 OPY1 and
37997 strains revealed that both have a histidine at this position.
Furthermore, while the LR2006 strain does display an increase in
viral replication within the muscle and induces more damage, we
have not observed differences in viral fitness. Similar replication of
the two strains was observed in several mammalian cell types,
including BHK cells, MEFs, and connective tissue fibroblasts (Fig.
1 and 6 anddata not shown), suggesting that the fitness of the virus
does not explain our in vivo phenotypes.
Previous to this study, direct infection of myofibers by CHIKV
had not been shown, though evidence of myofiber fragmentation
and necrosis has been reported (33). Since we observed the infec-
tion of myofibers following i.d. administration of the LR2006
OPY1 strain but not the 37997 strain, differences in cellular
tropism could also contribute to the altered pathogenesis. Muta-
tions in the LR strain could result in increased receptor binding
and/or replication within myoblasts or myofibers. However, our
in vitro studies demonstrated that both strains were able to infect
connective tissue fibroblasts, myoblasts, and myofibers, and the
viruses grew with similar kinetics and to similar titers (Fig. 6).
Furthermore, the administration of the 37997 strain directly into
the muscle resulted in myofiber infection and dramatically re-
duced the differences in viral titers seen between the two strains
(Fig. 6). Interestingly, while direct i.m. administration of the two
strains equalized the viral loads within the injected muscle and
allowed for 37997 to infect themyofibers, spread of the virus to the
contralateral muscle was more efficient for the LR2006 strain,
once again resulting in viral loads that were greater than 100-fold
higher than those seen with the 37997 strain (Fig. 6). These data
suggest that the LR2006OPY1 strainmay have an increased ability
to access myofibers.
Previous studies evaluating the ability of gene therapy viral
vectors, such as herpes simplex virus 1 (HSV-1) and adenoviruses,
to infect skeletal muscle have shown that the basal lamina can
function as a physical barrier to limit myofiber infection in adult
muscle. Intact skeletal muscle was not permissive to HSV-1 infec-
tion ofmyofibers, but isolatedmyofibers cultured in vitro could be
infected (36). The disruption of the basal lamina through the uti-
lization of genetically defectivemice (dy/dy) which have abnormal
basal lamina synthesis allowed for myofiber infection in vivo (37).
One potential explanation for the differential infection of myofi-
bers with our viruses is that during the course of the LR2006OPY1
infection, there is an alteration in the production of cytokines or
proteases that can damage the basal lamina surrounding the mus-
cle fibers, allowing the LR2006 OPY1 strain to establish infection.
Proinflammatory cytokines and chemokines are induced in ani-
mal models of CHIKV, and in human studies elevated levels of
IL-6, IL-1, and RANTES have been associated with more severe
disease manifestations (18). Infection with either the LR2006
OPY1 or the 37997 strain of CHIKV did induce a proinflamma-
tory cytokine and chemokine response; however, despite the pro-
longed serum viremia following LR2006 OPY1 infection, no sig-
nificant differences were observed between the two strains during
the course of infection (Fig. 3). We also did not observe a differ-
ence in the induction of type I IFNs either systemically or within
the muscle itself. While the levels of IFN did not differ, it is still
possible that there is differential induction of ISGs by these two
strains that contributes to differential control of viral replication
within themuscle fiber. A limited analysis of ISGs has not revealed
any differential expression within the muscle; however, a more
complete analysis is required to fully rule out this possibility. Al-
ternatively, within the context of the intact muscle architecture,
differential induction in the expression of receptors forCHIKVon
myoblasts or myofibers could account for differences in infectiv-
ity. Until the CHIKV receptor is identified, the latter hypothesis
cannot be formally tested. Whether the prolonged serum viremia
we observed during the LR2006 OPY1 infection also contributes
to the myofiber infection by allowing the LR2006 OPY1 virus to
reach higher concentrations along the basal lamina is unknown.
However, the prolonged viremia cannot account for the entire
muscle phenotype, as LR2006 OPY1-infected mice already have
high titers at 3 dpi, when both strains cause similar serum viremia
(Fig. 2).
Little is known about the viral determinants that regulate
CHIKV-induced disease, in particular its ability to target themus-
CHIKV Myoﬁber Infection in Mice
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culoskeletal system. Several studies have identified mutations
within the E2 protein in different alphaviruses to have a significant
impact upon virulence. The vaccine strain CHIKV 181/clone 25
was found to be attenuated in mice due to mutations in the E2
protein that arose during serial passaging in cell culture (38). Ad-
ditionally, a residue found to be responsible for controlling RRV
virulence in the muscle was localized to the E2 protein (35). To
critically evaluate the role that the E2 protein may play in the
ability to infect and replicate in the myofibers, we generated chi-
meric viruses in which the E2 proteins were exchanged, replacing
the E2 of the LR2006 strain with the 37997 E2 or making the
reciprocal virus (Fig. 7A). Following i.d. infectionwith the recom-
binant strains, we analyzed viral titers in the distal muscle, but in
both cases we found that the substitution of the E2 protein did not
alter the viral phenotype of the background virus, indicating that
the E2 protein, in isolation, was not responsible for the increased
replication within the muscle (Fig. 7B).
The prolonged serum viremia observed following LR2006
OPY1 infection could have many impacts upon CHIKV patho-
genesis. An increase in the length of time that a patient exhibits
high serum viremia would prolong the period of time in which a
patient can transmit the infection to a new mosquito host and
subsequently to another patient. It has previously been shown that
an alanine-to-valine mutation within the LR2006 OPY1 strain re-
sulted in increased infectivity of the Asian tiger mosquito, A.
albopictus. Therefore, a prolonged period of serum viremia cou-
pled with the ability of this strain to replicate to high titers in A.
albopictus could contribute to the ease with which CHIKV has
spread to infect many on La Reunion and ultimately millions in
Southeast Asia. A prolonged viremic phase could also contribute
tomore severe diseasemanifestations, especially in the elderly and
neonates with already-diminished immune systems. A prospec-
tive cohort study of patients on La Reunion found that those pa-
tients with chronic disease had higher viral loads than their coun-
terparts who recovered fully, suggesting a deficit in viral clearance
(39). Future studies evaluating whether the ability of CHIKV to
access and infect myofibers contributes to more severe disease
manifestations, such as the development of arthritis or the main-
tenance of chronic infection, will be important to further our un-
derstanding of CHIKV pathogenesis and in the identification of
therapeutic interventions.
ACKNOWLEDGMENTS
Funding for this project (D.J.L.) was provided by theChildren’sDiscovery
Institute of Washington University and St. Louis Children’s Hospital and
by NIH/NIAID 2 U54 AI057160-06. Work by J.C.C. was funded by NIH
grant EY018826. D.L.V. and S.H were in part supported by NIH AI R21
AI073389. G.K. was funded by NICHD/NIH R01 HD053728.
We thank Sam J. Mathew for his advice and training on culturing
muscle cell types.
REFERENCES
1. Robinson MC. 1955. An epidemic of virus disease in Southern Province,
Tanganyika Territory, in 1952-53. I. Clinical features. Trans. R. Soc. Trop.
Med. Hyg. 49:28–32. http://dx.doi.org/10.1016/0035-9203(55)90080-8.
2. Mavalankar D, Shastri P, Raman P. 2007. Chikungunya epidemic in
India: a major public-health disaster. Lancet Infect. Dis. 7:306–307. http:
//dx.doi.org/10.1016/S1473-3099(07)70091-9.
3. Jose J, Snyder JE, Kuhn RJ. 2009. A structural and functional perspective
of alphavirus replication and assembly. Fut. Microbiol. 4:837–856. http:
//dx.doi.org/10.2217/fmb.09.59.
4. Sourisseau M, Schilte C, Casartelli N, Trouillet C, Guivel-Benhassine F,
Rudnicka D, Sol-Foulon N, Le Roux K, Prevost MC, Fsihi H, Frenkiel
MP, Blanchet F, Afonso PV, Ceccaldi PE, Ozden S, Gessain A, Schuff-
enecker I, Verhasselt B, Zamborlini A, Saib A, Rey FA, Arenzana-
Seisdedos F, Despres P, Michault A, Albert ML, Schwartz O. 2007.
Characterization of reemerging chikungunya virus. PLoS Pathog. 3:e89.
http://dx.doi.org/10.1371/journal.ppat.0030089.
5. Borgherini G, Poubeau P, Jossaume A, Gouix A, Cotte L, Michault A,
Arvin-Berod C, Paganin F. 2008. Persistent arthralgia associated with
chikungunya virus: a study of 88 adult patients on reunion island. Clin.
Infect. Dis. 47:469–475. http://dx.doi.org/10.1086/590003.
6. Carmona RJ, Shaikh S, Khalidi NA. 2008. Chikungunya viral polyarthri-
tis. J. Rheumatol. 35:935–936.
7. Parola P, Simon F, Oliver M. 2007. Tenosynovitis and vascular disorders
associated with chikungunya virus-related rheumatism. Clin. Infect. Dis.
45:801–802. http://dx.doi.org/10.1086/521171.
8. Economopoulou A, Dominguez M, Helynck B, Sissoko D, Wichmann
O, Quenel P, Germonneau P, Quatresous I. 2009. Atypical chikungunya
virus infections: clinical manifestations, mortality and risk factors for se-
vere disease during the 2005-2006 outbreak on Reunion. Epidemiol. In-
fect. 137:534–541. http://dx.doi.org/10.1017/S0950268808001167.
9. Das T, Jaffar-Bandjee MC, Hoarau JJ, Krejbich Trotot P, Denizot M,
Lee-Pat-Yuen G, Sahoo R, Guiraud P, Ramful D, Robin S, Alessandri
JL, Gauzere BA, Gasque P. 2010. Chikungunya fever: CNS infection and
pathologies of a re-emerging arbovirus. Prog. Neurobiol. 91:121–129.
http://dx.doi.org/10.1016/j.pneurobio.2009.12.006.
10. Tandale BV, Sathe PS, Arankalle VA, Wadia RS, Kulkarni R, Shah SV,
Shah SK, Sheth JK, Sudeep AB, Tripathy AS, Mishra AC. 2009. Systemic
involvements and fatalities during chikungunya epidemic in India, 2006.
J. Clin. Virol. 46:145–149. http://dx.doi.org/10.1016/j.jcv.2009.06.027.
11. Gerardin P, Barau G, Michault A, Bintner M, Randrianaivo H, Choker
G, Lenglet Y, Touret Y, Bouveret A, Grivard P, Le Roux K, Blanc S,
Schuffenecker I, Couderc T, Arenzana-Seisdedos F, Lecuit M, Robillard
PY. 2008.Multidisciplinary prospective study of mother-to-child chikun-
gunya virus infections on the island of La Reunion. PLoS Med. 5:e60.
http://dx.doi.org/10.1371/journal.pmed.0050060.
12. Tsetsarkin KA, Vanlandingham DL, McGee CE, Higgs S. 2007. A single
mutation in chikungunya virus affects vector specificity and epidemic
FIG 7 The E2 protein of LR2006 OPY1 strain of CHIKV is not responsible for
the increased replication in the muscle fibers. (A) Chimeric viruses were con-
structed by swapping the E2 from one strain into the backbone of the other as
shown in the schematic. Mice were infected by each strain at a dose of 5 104
PFU intradermally. (B) Hind limbs were harvested at 5 dpi, and titers were
determined by plaque assay (n 3 or 4).
Rohatgi et al.




arch 1, 2014 by W






potential. PLoS Pathog. 3:e201. http://dx.doi.org/10.1371/journal.ppat
.0030201.
13. Rezza G, Nicoletti L, Angelini R, Romi R, Finarelli AC, Panning M,
Cordioli P, Fortuna C, Boros S, Magurano F, Silvi G, Angelini P,
Dottori M, Ciufolini MG, Majori GC, Cassone A. 2007. Infection with
chikungunya virus in Italy: an outbreak in a temperate region. Lancet
370:1840–1846. http://dx.doi.org/10.1016/S0140-6736(07)61779-6.
14. Gould EA, Gallian P, De Lamballerie X, Charrel RN. 2010. First cases of
autochthonous dengue fever and chikungunya fever in France: from bad
dream to reality! Clin. Microbiol. Infect. 16:1702–1704. http://dx.doi.org
/10.1111/j.1469-0691.2010.03386.x.
15. Gibney KB, Fischer M, Prince HE, Kramer LD, St George K, Kosoy OL,
Laven JJ, Staples JE. 2011. Chikungunya fever in the United States: a
fifteen year review of cases. Clin. Infect. Dis. 52:e121–126. http://dx.doi
.org/10.1093/cid/ciq214.
16. Couderc T, Chretien F, Schilte C, Disson O, Brigitte M, Guivel-
Benhassine F, Touret Y, Barau G, Cayet N, Schuffenecker I, Despres P,
Arenzana-Seisdedos F, Michault A, Albert ML, Lecuit M. 2008. A mouse
model for chikungunya: young age and inefficient type-I interferon sig-
naling are risk factors for severe disease. PLoS Pathog. 4:e29. http://dx.doi
.org/10.1371/journal.ppat.0040029.
17. Ozden S, Huerre M, Riviere JP, Coffey LL, Afonso PV, Mouly V, de
Monredon J, Roger JC, El Amrani M, Yvin JL, Jaffar MC, Frenkiel MP,
Sourisseau M, Schwartz O, Butler-Browne G, Despres P, Gessain A,
Ceccaldi PE. 2007. Humanmuscle satellite cells as targets of chikungunya
virus infection. PLoS One 2:e527. http://dx.doi.org/10.1371/journal.pone
.0000527.
18. Ng LF, Chow A, Sun YJ, Kwek DJ, Lim PL, Dimatatac F, Ng LC, Ooi EE,
Choo KH, Her Z, Kourilsky P, Leo YS. 2009. IL-1beta, IL-6, and RAN-
TES as biomarkers of chikungunya severity. PLoS One 4:e4261. http://dx
.doi.org/10.1371/journal.pone.0004261.
19. Vanlandingham DL, Tsetsarkin K, Hong C, Klingler K, McElroy KL,
LehaneMJ, Higgs S. 2005. Development and characterization of a double
subgenomic chikungunya virus infectious clone to express heterologous
genes in Aedes aegypti mosquitoes. Insect Biochem. Mol. Biol. 35:1162–
1170. http://dx.doi.org/10.1016/j.ibmb.2005.05.008.
20. Tsetsarkin K, Higgs S, McGee CE, De Lamballerie X, Charrel RN,
Vanlandingham DL. 2006. Infectious clones of chikungunya virus (La
Reunion isolate) for vector competence studies. Vector Borne Zoonot.
Dis. 6:325–337. http://dx.doi.org/10.1089/vbz.2006.6.325.
21. Schuffenecker I, Iteman I, Michault A, Murri S, Frangeul L, Vaney MC,
Lavenir R, Pardigon N, Reynes JM, Pettinelli F, Biscornet L, Diancourt
L, Michel S, Duquerroy S, Guigon G, Frenkiel MP, Brehin AC, Cubito
N, Despres P, Kunst F, Rey FA, Zeller H, Brisse S. 2006. Genome
microevolution of chikungunya viruses causing the Indian Ocean
outbreak. PLoS Med. 3:e263. http://dx.doi.org/10.1371/journal.pmed
.0030263.
22. Tsetsarkin KA, McGee CE, Volk SM, Vanlandingham DL, Weaver SC,
Higgs S. 2009. Epistatic roles of E2 glycoprotein mutations in adaption of
chikungunya virus to Aedes albopictus and Ae. aegypti mosquitoes. PLoS
One 4:e6835. http://dx.doi.org/10.1371/journal.pone.0006835.
23. National Research Council. 2011. Guide for the care and use of laboratory
animals, 8th ed. National Academies Press, Washington, DC.
24. Lenschow DJ, Giannakopoulos NV, Gunn LJ, Johnston C, O’Guin AK,
Schmidt RE, Levine B, Virgin HW, IV. 2005. Identification of interferon-
stimulated gene 15 as an antiviral molecule during Sindbis virus infection
in vivo. J. Virol. 79:13974–13983. http://dx.doi.org/10.1128/JVI.79.22
.13974-13983.2005.
25. Werneke SW, Schilte C, Rohatgi A, Monte KJ, Michault A, Arenzana-
Seisdedos F, Vanlandingham DL, Higgs S, Fontanet A, Albert ML,
Lenschow DJ. 2011. ISG15 is critical in the control of chikungunya virus
infection independent of UbE1L mediated conjugation. PLoS Pathog.
7:e1002322. http://dx.doi.org/10.1371/journal.ppat.1002322.
26. Mathew SJ, Hansen JM, Merrell AJ, Murphy MM, Lawson JA,
Hutcheson DA, Hansen MS, Angus-Hill M, Kardon G. 2011. Connec-
tive tissue fibroblasts and Tcf4 regulate myogenesis. Development 138:
371–384. http://dx.doi.org/10.1242/dev.057463.
27. Daffis S, Samuel MA, Keller BC, Gale M, Jr, Diamond MS. 2007.
Cell-specific IRF-3 responses protect against West Nile virus infection by
interferon-dependent and -independent mechanisms. PLoS Pathog.
3:e106. http://dx.doi.org/10.1371/journal.ppat.0030106.
28. Strong DW, Thackray LB, Smith TJ, Virgin HW. 2012. Protruding
domain of capsid protein is necessary and sufficient to determine murine
norovirus replication and pathogenesis in vivo. J. Virol. 86:2950–2958.
http://dx.doi.org/10.1128/JVI.07038-11.
29. Frolova EI, Fayzulin RZ, Cook SH, Griffin DE, Rice CM, Frolov I. 2002.
Roles of nonstructural protein nsP2 and alpha/beta interferons in deter-
mining the outcome of Sindbis virus infection. J. Virol. 76:11254–11264.
http://dx.doi.org/10.1128/JVI.76.22.11254-11264.2002.
30. Rosenblum CI, Stollar V. 1999. SVMPA, a mutant of Sindbis virus resis-
tant to mycophenolic acid and ribavirin, shows an increased sensitivity to
chick interferon. Virology 259:228–233. http://dx.doi.org/10.1006/viro
.1999.9775.
31. Ziegler SA, Lu L, da Rosa AP, Xiao SY, Tesh RB. 2008. An animal model
for studying the pathogenesis of chikungunya virus infection. Am. J. Trop.
Med. Hyg. 79:133–139.
32. Klimstra WB, Ryman KD, Bernard KA, Nguyen KB, Biron CA, John-
ston RE. 1999. Infection of neonatal mice with Sindbis virus results in a
systemic inflammatory response syndrome. J. Virol. 73:10387–10398.
33. Chen CI, Clark DC, Pesavento P, Lerche NW, Luciw PA, Reisen WK,
Brault AC. 2010. Comparative pathogenesis of epidemic and enzootic
chikungunya viruses in a pregnant rhesus macaque model. Am. J. Trop.
Med.Hyg. 83:1249–1258. http://dx.doi.org/10.4269/ajtmh.2010.10-0290.
34. Gardner J, Anraku I, Le TT, Larcher T, Major L, Roques P, Schroder
WA, Higgs S, Suhrbier A. 2010. Chikungunya virus arthritis in adult
wild-type mice. J. Virol. 84:8021–8032. http://dx.doi.org/10.1128/JVI
.02603-09.
35. Jupille HJ, Medina-Rivera M, Hawman DW, Oko L, Morrison TE.
2013. A tyrosine-to-histidine switch at position 18 of the Ross River virus
E2 glycoprotein is a determinant of virus fitness in disparate hosts. J. Virol.
87:5970–5984. http://dx.doi.org/10.1128/JVI.03326-12.
36. Huard J, Feero WG, Watkins SC, Hoffman EP, Rosenblatt DJ, Glorioso
JC. 1996. The basal lamina is a physical barrier to herpes simplex virus-
mediated gene delivery to mature muscle fibers. J. Virol. 70:8117–8123.
37. Feero WG, Rosenblatt JD, Huard J, Watkins SC, Epperly M, Clemens
PR, Kochanek S, Glorioso JC, Partridge TA, Hoffman EP. 1997. Viral
gene delivery to skeletal muscle: insights onmaturation-dependent loss of
fiber infectivity for adenovirus and herpes simplex type 1 viral vectors.
Hum. Gene Ther. 8:371–380. http://dx.doi.org/10.1089/hum.1997.8.4
-371.
38. Gorchakov R, Wang E, Leal G, Forrester NL, Plante K, Rossi SL,
Partidos CD, Adams AP, Seymour RL, Weger J, Borland EM, Sherman
MB, Powers AM, Osorio JE, Weaver SC. 2012. Attenuation of chikun-
gunya virus vaccine strain 181/clone 25 is determined by two amino acid
substitutions in the E2 envelope glycoprotein. J. Virol. 86:6084–6096.
http://dx.doi.org/10.1128/JVI.06449-11.
39. Hoarau JJ, Jaffar Bandjee MC, Krejbich Trotot P, Das T, Li-Pat-Yuen G,
Dassa B, Denizot M, Guichard E, Ribera A, Henni T, Tallet F, Moiton
MP, Gauzere BA, Bruniquet S, Jaffar Bandjee Z, Morbidelli P, Martigny
G, Jolivet M, Gay F, Grandadam M, Tolou H, Vieillard V, Debre P,
Autran B, Gasque P. 2010. Persistent chronic inflammation and infection
by chikungunya arthritogenic alphavirus in spite of a robust host immune
response. J. Immunol. 184:5914–5927. http://dx.doi.org/10.4049
/jimmunol.0900255.
CHIKV Myoﬁber Infection in Mice




arch 1, 2014 by W
ashington University in St. Louis
http://jvi.asm.org/
D
ow
nloaded from
 
